Updated clinical practice guidelines for the prevention and treatment of mucositis

Dorothy M. Keefe, Mark M. Schubert, Linda S. Elting, Stephen T. Sonis, Joel B. Epstein, Judith E. Raber-Durlacher, Cesar Migliorati, Deborah B. McGuire, Ronald D. Hutchins, Douglas E. Peterson

Research output: Contribution to journalReview article

521 Citations (Scopus)

Abstract

Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition has been approved by the United States Food and Drug Administration and other regulatory agencies in Europe and Australia. These changes necessitate an updated review of the literature and guidelines. Panel members reviewed the biomedical literature on mucositis published in English between January 2002 and May 2005 and reached a consensus based on the criteria of the American Society of Clinical Oncology. Changes in the guidelines included recommendations for the use of palifermin for oral mucositis associated with stem cell transplantation, amifostine for radiation proctitis, and cryotherapy for mucositis associated with high-dose melphalan. Recommendations against specific practices were introduced: Systemic glutamine was not recommended for the prevention of gastro-intestinal mucositis, and sucralfate and antimicrobial lozenges were not recommended for radiation-induced oral mucositis. Furthermore, new guidelines suggested that granulocyte-macrophage-colony stimulating factor mouthwashes not be used for oral mucositis prevention in the transplantation population. Advances in mucositis treatment and research have been complemented by an increased rate of publication on mucosal injury in cancer. However, additional and sustained efforts will be required to gain a fuller understanding of the pathobiology, impact on overall patient status, optimal therapeutic strategies, and improved educational programs for health professionals, patients, and caregivers. These efforts are likely to have significant clinical and economic impact on the treatment of cancer patients.

Original languageEnglish (US)
Pages (from-to)820-831
Number of pages12
JournalCancer
Volume109
Issue number5
DOIs
StatePublished - Mar 1 2007

Fingerprint

Mucositis
Practice Guidelines
Stomatitis
Guidelines
Amifostine
Mouthwashes
Fibroblast Growth Factor 7
Radiation
Sucralfate
Proctitis
Therapeutics
Neoplasms
Cryotherapy
Melphalan
Stem Cell Transplantation
United States Food and Drug Administration
Granulocyte-Macrophage Colony-Stimulating Factor
Glutamine
Research
Caregivers

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Keefe, D. M., Schubert, M. M., Elting, L. S., Sonis, S. T., Epstein, J. B., Raber-Durlacher, J. E., ... Peterson, D. E. (2007). Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer, 109(5), 820-831. https://doi.org/10.1002/cncr.22484

Updated clinical practice guidelines for the prevention and treatment of mucositis. / Keefe, Dorothy M.; Schubert, Mark M.; Elting, Linda S.; Sonis, Stephen T.; Epstein, Joel B.; Raber-Durlacher, Judith E.; Migliorati, Cesar; McGuire, Deborah B.; Hutchins, Ronald D.; Peterson, Douglas E.

In: Cancer, Vol. 109, No. 5, 01.03.2007, p. 820-831.

Research output: Contribution to journalReview article

Keefe, DM, Schubert, MM, Elting, LS, Sonis, ST, Epstein, JB, Raber-Durlacher, JE, Migliorati, C, McGuire, DB, Hutchins, RD & Peterson, DE 2007, 'Updated clinical practice guidelines for the prevention and treatment of mucositis', Cancer, vol. 109, no. 5, pp. 820-831. https://doi.org/10.1002/cncr.22484
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007 Mar 1;109(5):820-831. https://doi.org/10.1002/cncr.22484
Keefe, Dorothy M. ; Schubert, Mark M. ; Elting, Linda S. ; Sonis, Stephen T. ; Epstein, Joel B. ; Raber-Durlacher, Judith E. ; Migliorati, Cesar ; McGuire, Deborah B. ; Hutchins, Ronald D. ; Peterson, Douglas E. / Updated clinical practice guidelines for the prevention and treatment of mucositis. In: Cancer. 2007 ; Vol. 109, No. 5. pp. 820-831.
@article{7963fe669f244d8bb93d9228b1d71c9c,
title = "Updated clinical practice guidelines for the prevention and treatment of mucositis",
abstract = "Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition has been approved by the United States Food and Drug Administration and other regulatory agencies in Europe and Australia. These changes necessitate an updated review of the literature and guidelines. Panel members reviewed the biomedical literature on mucositis published in English between January 2002 and May 2005 and reached a consensus based on the criteria of the American Society of Clinical Oncology. Changes in the guidelines included recommendations for the use of palifermin for oral mucositis associated with stem cell transplantation, amifostine for radiation proctitis, and cryotherapy for mucositis associated with high-dose melphalan. Recommendations against specific practices were introduced: Systemic glutamine was not recommended for the prevention of gastro-intestinal mucositis, and sucralfate and antimicrobial lozenges were not recommended for radiation-induced oral mucositis. Furthermore, new guidelines suggested that granulocyte-macrophage-colony stimulating factor mouthwashes not be used for oral mucositis prevention in the transplantation population. Advances in mucositis treatment and research have been complemented by an increased rate of publication on mucosal injury in cancer. However, additional and sustained efforts will be required to gain a fuller understanding of the pathobiology, impact on overall patient status, optimal therapeutic strategies, and improved educational programs for health professionals, patients, and caregivers. These efforts are likely to have significant clinical and economic impact on the treatment of cancer patients.",
author = "Keefe, {Dorothy M.} and Schubert, {Mark M.} and Elting, {Linda S.} and Sonis, {Stephen T.} and Epstein, {Joel B.} and Raber-Durlacher, {Judith E.} and Cesar Migliorati and McGuire, {Deborah B.} and Hutchins, {Ronald D.} and Peterson, {Douglas E.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1002/cncr.22484",
language = "English (US)",
volume = "109",
pages = "820--831",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Updated clinical practice guidelines for the prevention and treatment of mucositis

AU - Keefe, Dorothy M.

AU - Schubert, Mark M.

AU - Elting, Linda S.

AU - Sonis, Stephen T.

AU - Epstein, Joel B.

AU - Raber-Durlacher, Judith E.

AU - Migliorati, Cesar

AU - McGuire, Deborah B.

AU - Hutchins, Ronald D.

AU - Peterson, Douglas E.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition has been approved by the United States Food and Drug Administration and other regulatory agencies in Europe and Australia. These changes necessitate an updated review of the literature and guidelines. Panel members reviewed the biomedical literature on mucositis published in English between January 2002 and May 2005 and reached a consensus based on the criteria of the American Society of Clinical Oncology. Changes in the guidelines included recommendations for the use of palifermin for oral mucositis associated with stem cell transplantation, amifostine for radiation proctitis, and cryotherapy for mucositis associated with high-dose melphalan. Recommendations against specific practices were introduced: Systemic glutamine was not recommended for the prevention of gastro-intestinal mucositis, and sucralfate and antimicrobial lozenges were not recommended for radiation-induced oral mucositis. Furthermore, new guidelines suggested that granulocyte-macrophage-colony stimulating factor mouthwashes not be used for oral mucositis prevention in the transplantation population. Advances in mucositis treatment and research have been complemented by an increased rate of publication on mucosal injury in cancer. However, additional and sustained efforts will be required to gain a fuller understanding of the pathobiology, impact on overall patient status, optimal therapeutic strategies, and improved educational programs for health professionals, patients, and caregivers. These efforts are likely to have significant clinical and economic impact on the treatment of cancer patients.

AB - Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition has been approved by the United States Food and Drug Administration and other regulatory agencies in Europe and Australia. These changes necessitate an updated review of the literature and guidelines. Panel members reviewed the biomedical literature on mucositis published in English between January 2002 and May 2005 and reached a consensus based on the criteria of the American Society of Clinical Oncology. Changes in the guidelines included recommendations for the use of palifermin for oral mucositis associated with stem cell transplantation, amifostine for radiation proctitis, and cryotherapy for mucositis associated with high-dose melphalan. Recommendations against specific practices were introduced: Systemic glutamine was not recommended for the prevention of gastro-intestinal mucositis, and sucralfate and antimicrobial lozenges were not recommended for radiation-induced oral mucositis. Furthermore, new guidelines suggested that granulocyte-macrophage-colony stimulating factor mouthwashes not be used for oral mucositis prevention in the transplantation population. Advances in mucositis treatment and research have been complemented by an increased rate of publication on mucosal injury in cancer. However, additional and sustained efforts will be required to gain a fuller understanding of the pathobiology, impact on overall patient status, optimal therapeutic strategies, and improved educational programs for health professionals, patients, and caregivers. These efforts are likely to have significant clinical and economic impact on the treatment of cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=33847389418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847389418&partnerID=8YFLogxK

U2 - 10.1002/cncr.22484

DO - 10.1002/cncr.22484

M3 - Review article

VL - 109

SP - 820

EP - 831

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -